100 Participants Needed

High Dose Albumin for Ascites

PJ
Overseen ByPrasun Jalal, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Baylor College of Medicine
Must be taking: Albumin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, since the trial focuses on patients with refractory ascites who are already on maximum tolerable doses of diuretics, it seems likely that you may continue your current treatment.

What data supports the effectiveness of the drug for treating ascites?

Research shows that long-term use of human albumin can improve survival and reduce hospitalizations in patients with cirrhosis and ascites. It is also effective in preventing complications like kidney failure and circulatory issues after certain medical procedures.12345

Is high dose albumin generally safe for humans?

Previous studies have shown that human albumin has a low rate of serious side effects, although some incidents might be under-reported. Overall, it is considered safe for use in humans.678910

How does the drug albumin differ from other treatments for ascites?

Albumin is unique because it acts as a plasma expander, helping to restore blood volume and pressure, which can improve the body's response to diuretics and prevent complications after fluid removal. It is particularly effective in preventing circulatory dysfunction after large-volume paracentesis and in reducing the risk of kidney problems in patients with liver cirrhosis.1341112

What is the purpose of this trial?

Advanced cirrhosis with complications is a serious problem imposing a heavy financial burden on health care system. Moreover, ascites is associated with increase in mortality rates among cirrhotic patients. Ascites pathogenesis is multifactorial including: portal hypertension; splanchnic and peripheral arterial vasodilation; and neurohumoral activation. Current management strategies include dietary sodium restriction and diuretic therapy, however, this strategy put patients at the risk of intravascular volume depletion, renal impairment, hepatic encephalopathy and hyponatremia. Moreover, around 10% of patients do not respond to this strategy (termed: diuretics resistant) with 50% of them die within 6 months. This sub-group is managed by frequent large volume paracentesis along with intravenous albumin administration and are usually considered for liver transplantation (LT) and TIPS. Nonetheless, Frequent paracentesis increases the risk of infection, bleeding, bowel perforation, paracentesis-induced circulatory dysfunction (PICD) and renal dysfunction in this sub-group of patients. The beneficial effect of human albumin might result from blood volume expansion tapering activated vasoconstrictor and sodium-retaining systems improving renal perfusion, hence regular infusion of albumin may be beneficial to prevent development of ascites and to improve survival. The positive effects of albumin are supported by previous studies; Romanelli et al, showed a significant increase in survival rate among cirrhotic patients with ascites when compared to those who did not receive albumin. Moreover, a randomized multicenter open label trial published in lancet last year, demonstrated that long term albumin administration improved 18-month survival, decreased the use of paracentesis and decrease in the incidence of cirrhosis related complications among cirrhotic patients with ascites. As of today, there's a limited use of regular high dose albumin in cirrhotic patients with ascites in US, despite being used elsewhere in the world as previously stated.The investigators wish to study long-term efficacy of human albumin administration in patients with decompensated cirrhosis to assess safety and efficacy, and prevention of complications of cirrhosis.

Research Team

PJ

Prasun Jalal, MD

Principal Investigator

Baylor College of Medicine

Eligibility Criteria

This trial is for adults over 18 with liver cirrhosis and refractory ascites, which means their body retains fluid despite maximum diuretic treatment and often needs excess fluid removed.

Inclusion Criteria

My ascites hasn't improved despite maximum diuretic treatment and needs frequent draining.
I am older than 18 years.
I have been diagnosed with liver cirrhosis.

Exclusion Criteria

I have never had liver cirrhosis.
I have fluid in my abdomen not caused by heart or cancer issues.
I am under 18 years old.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Participants receive either high-dose albumin or standard care for up to one year

12 months
Monthly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks
1 visit (in-person)

Open-label extension (optional)

Participants may opt into continuation of treatment long-term

Long-term

Treatment Details

Interventions

  • Albumin
Trial Overview The study tests the long-term effects of high-dose human albumin in patients with advanced liver disease to see if it can prevent complications and improve survival by expanding blood volume.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention armExperimental Treatment1 Intervention
the intervention group will receive intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g, plus SOC
Group II: Control armActive Control1 Intervention
the control arm will receive the standard of care (SOC), including moderate sodium restriction, maximal daily tolerated doses of diuretics, and post-paracentesis albumin

Albumin is already approved in United States, European Union, Japan for the following indications:

🇺🇸
Approved in United States as Albumin for:
  • Acute Liver Failure
  • Adult Respiratory Distress Syndrome
  • Burns
  • Cardiopulmonary Bypass
  • Hypoalbuminemia
  • Hemodialysis
  • Hypovolemia
  • Ovarian Hyperstimulation Syndrome
🇪🇺
Approved in European Union as Albumin for:
  • Hypoalbuminemia
  • Hypovolemia
  • Ascites
  • Spontaneous Bacterial Peritonitis
  • Hepatic Encephalopathy
  • Hepatorenal Syndrome
🇯🇵
Approved in Japan as Albumin for:
  • Hypoalbuminemia
  • Hypovolemia
  • Ascites
  • Spontaneous Bacterial Peritonitis

Find a Clinic Near You

Who Is Running the Clinical Trial?

Baylor College of Medicine

Lead Sponsor

Trials
1,044
Recruited
6,031,000+

Findings from Research

Long-term administration of albumin significantly improved the normalization rate of hyponatremia in patients with ascites, achieving 45% normalization compared to 28% with standard treatment after one month.
Patients receiving long-term albumin treatment experienced a much lower incidence of at least moderate hyponatremia over 18 months, with an incidence rate ratio of 0.245, indicating a strong protective effect against worsening hyponatremia.
Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database.Zaccherini, G., Baldassarre, M., Tufoni, M., et al.[2023]
In a study of 100 patients with first-onset ascites, those receiving long-term albumin treatment alongside diuretics had a significantly higher survival rate compared to those receiving diuretics alone, with an average increase in survival of 16 months.
Patients treated with albumin also experienced a much lower recurrence rate of ascites (51% compared to 94% in the control group), indicating that albumin administration can effectively reduce complications associated with ascites.
Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.Romanelli, RG., La Villa, G., Barletta, G., et al.[2019]
In a study of 38 patients with advanced cirrhotic ascites, the administration of human serum albumin (HSA) significantly increased serum albumin levels and led to weight loss, indicating its efficacy in managing this condition.
The weight loss observed was directly correlated with the total amount of HSA administered, suggesting that higher doses may enhance the therapeutic effects in patients undergoing diuretic therapy.
Contribution of diuretic therapy with human serum albumin to the management of ascites in patients with advanced liver cirrhosis: A prospective cohort study.Nakamura, T., Sata, M., Hiroishi, K., et al.[2021]

References

Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database. [2023]
Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. [2019]
Contribution of diuretic therapy with human serum albumin to the management of ascites in patients with advanced liver cirrhosis: A prospective cohort study. [2021]
4.United Arab Emiratespubmed.ncbi.nlm.nih.gov
The use of human albumin for the treatment of ascites in patients with liver cirrhosis: item of safety, facts, controversies and perspectives. [2022]
Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. [2020]
Safety of human albumin--serious adverse events reported worldwide in 1998-2000. [2022]
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. [2023]
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). [2022]
Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. [2023]
Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system. [2023]
[The use of albumin infusion in decompensated liver cirrhosis]. [2007]
Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security